Compare Stocks: ANNX, TLX, DNLI, and RCUS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$5.07 -2.1%	$5.38	$2.03 ▼ $7.18	$961.17M	1.18	2.59 million shs	1.43 million shs
DNLI Denali Therapeutics	$24.92 -0.1%	$24.45	$12.58 ▼ $27.30	$3.98B	1.01	1.39 million shs	680,991 shs
RCUS Arcus Biosciences	$30.14 +2.1%	$28.50	$10.07 ▼ $31.74	$3.86B	0.8	1.24 million shs	1.06 million shs
TLX Telix Pharmaceuticals	$11.33 -8.8%	$10.96	$6.28 ▼ $12.60	$3.85B	-0.24	105,175 shs	299,619 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	0.00%	-4.16%	-4.34%	-4.52%	+136.92%
DNLI Denali Therapeutics	0.00%	+2.13%	+6.40%	+33.69%	+71.74%
RCUS Arcus Biosciences	0.00%	+2.18%	+1.44%	+28.39%	+198.86%
TLX Telix Pharmaceuticals	0.00%	-4.15%	+7.80%	+19.64%	+3.28%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$5.07 -2.1%	$5.38	$2.03 ▼ $7.18	$961.17M	1.18	2.59 million shs	1.43 million shs
DNLI Denali Therapeutics	$24.92 -0.1%	$24.45	$12.58 ▼ $27.30	$3.98B	1.01	1.39 million shs	680,991 shs
RCUS Arcus Biosciences	$30.14 +2.1%	$28.50	$10.07 ▼ $31.74	$3.86B	0.8	1.24 million shs	1.06 million shs
TLX Telix Pharmaceuticals	$11.33 -8.8%	$10.96	$6.28 ▼ $12.60	$3.85B	-0.24	105,175 shs	299,619 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	0.00%	-4.16%	-4.34%	-4.52%	+136.92%
DNLI Denali Therapeutics	0.00%	+2.13%	+6.40%	+33.69%	+71.74%
RCUS Arcus Biosciences	0.00%	+2.18%	+1.44%	+28.39%	+198.86%
TLX Telix Pharmaceuticals	0.00%	-4.15%	+7.80%	+19.64%	+3.28%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANNX Annexon	2.33	Hold	$15.33	202.43% Upside
DNLI Denali Therapeutics	2.75	Moderate Buy	$35.92	44.13% Upside
RCUS Arcus Biosciences	2.58	Moderate Buy	$37.80	25.41% Upside
TLX Telix Pharmaceuticals	2.75	Moderate Buy	$20.40	80.05% Upside

Current Analyst Ratings Breakdown

Latest ANNX, TLX, DNLI, and RCUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	TLX Telix Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Hold (C-)
8/20/2026	TLX Telix Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$22.00
8/13/2026	ANNX Annexon	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform
8/10/2026	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$23.00
8/7/2026	DNLI Denali Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$25.00 ➝ $34.00
8/7/2026	DNLI Denali Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$34.00
8/7/2026	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$42.00
8/6/2026	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$41.00 ➝ $43.00
8/6/2026	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$23.00 ➝ $26.00
7/23/2026	DNLI Denali Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$35.00 ➝ $36.00

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANNX Annexon	N/A	N/A	N/A	N/A	$0.98 per share	N/A
DNLI Denali Therapeutics	$330.53M	12.05	N/A	N/A	$5.22 per share	4.77
RCUS Arcus Biosciences	$247M	15.54	N/A	N/A	$3.64 per share	8.28
TLX Telix Pharmaceuticals	$803.79M	4.79	$0.04 per share	268.72	$1.23 per share	9.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANNX Annexon	-$206.69M	-$1.16	N/A	N/A	N/A	N/A	-106.15%	-79.82%	11/9/2026 (Estimated)
DNLI Denali Therapeutics	-$512.54M	-$2.84	N/A	N/A	N/A	N/A	-55.27%	-44.24%	11/5/2026 (Estimated)
RCUS Arcus Biosciences	-$353M	-$3.90	N/A	N/A	N/A	-393.16%	-89.54%	-45.61%	10/27/2026 (Estimated)
TLX Telix Pharmaceuticals	-$7.12M	N/A	N/A	188.83	N/A	N/A	N/A	N/A	N/A

Latest ANNX, TLX, DNLI, and RCUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ANNX Annexon	-$0.2388	-$0.28	-$0.0412	-$0.28	$6.50 million	N/A
8/6/2026	Q2 2026	DNLI Denali Therapeutics	-$0.5131	-$0.68	-$0.1670	-$0.68	$2.15 million	$3.60 million
8/5/2026	Q2 2026	RCUS Arcus Biosciences	-$0.8912	-$0.72	+$0.1712	-$0.72	$21.98 million	$41.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANNX Annexon	N/A	5.53	5.53
DNLI Denali Therapeutics	0.01	8.37	8.32
RCUS Arcus Biosciences	0.22	3.82	3.82
TLX Telix Pharmaceuticals	1.08	1.43	1.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANNX Annexon	N/A
DNLI Denali Therapeutics	92.92%
RCUS Arcus Biosciences	92.89%
TLX Telix Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ANNX Annexon	10.31%
DNLI Denali Therapeutics	9.70%
RCUS Arcus Biosciences	7.60%
TLX Telix Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANNX Annexon	60	189.58 million	170.03 million	Optionable
DNLI Denali Therapeutics	430	159.85 million	144.34 million	Optionable
RCUS Arcus Biosciences	500	127.33 million	117.66 million	Optionable
TLX Telix Pharmaceuticals	1,184	339.78 million	N/A	N/A

ANNX, TLX, DNLI, and RCUS Headlines

Recent News About These Companies

Wedbush Reaffirms "Outperform" Rating for Telix Pharmaceuticals (NASDAQ:TLX)

August 22 at 2:18 AM | americanbankingnews.com

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's What Happened

August 21 at 10:59 AM | marketbeat.com

HotCopper highlights: Zip dominates investor attention as Telix, Liontown and American Tungsten trend

August 21 at 7:43 AM | msn.com

Why were Telix shares just downgraded?

August 20 at 8:13 PM | fool.com.au

Telix Pharmaceuticals Limited (TLX) Stock: EBITDA Surges 146% as Revenue Hits $477M

August 20 at 4:31 PM | blockonomi.com

Telix Pharmaceuticals Limited: Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline

August 20 at 3:10 PM | finanznachrichten.de

Telix Pharmaceuticals (NASDAQ:TLX) Receives "Outperform" Rating from Wedbush

August 20 at 1:11 PM | marketbeat.com

Telix Pharmaceuticals (NASDAQ:TLX) Announces Earnings Results

August 20 at 8:55 AM | marketbeat.com

Telix half-year revenue increases 22 per cent to 477 million dollars

August 20 at 4:28 AM | vir.com.vnV

Telix Pharmaceuticals Limited (TLX) Q2 2026 Earnings Call Transcript

August 20 at 2:00 AM | seekingalpha.com

Telix Pharmaceuticals Limited 2026 Q2 - Results - Earnings Call Presentation

August 19, 2026 | seekingalpha.com

Telix Pharmaceuticals delivers robust half-year earnings and pipeline progress

August 19, 2026 | msn.com

Telix Pharmaceuticals H1 Earnings Call Highlights

August 19, 2026 | marketbeat.com

Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline

August 19, 2026 | globenewswire.com

Telix Pharmaceuticals (NASDAQ:TLX) Trading Down 4.3% - Should You Sell?

August 14, 2026 | marketbeat.com

Telix Pharmaceuticals (TLX) Expected to Announce Earnings on Thursday

August 13, 2026 | americanbankingnews.com

Telix Pharmaceuticals (TLX) to Release Quarterly Earnings on Thursday

August 13, 2026 | marketbeat.com

Telix Pharmaceuticals Ltd. ADR

August 12, 2026 | marketwatch.com

Hennion & Walsh Asset Management Inc. Takes Position in Telix Pharmaceuticals Limited $TLX

August 12, 2026 | marketbeat.com

Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

August 9, 2026 | marketbeat.com

Telix to host R&D Day in New York on 22 September

August 6, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX, TLX, DNLI, and RCUS Company Descriptions

Annexon NASDAQ:ANNX

$5.07 -0.11 (-2.12%)

As of 08/21/2026 04:00 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Denali Therapeutics NASDAQ:DNLI

$24.92 -0.03 (-0.12%)

As of 08/21/2026 04:00 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Arcus Biosciences NYSE:RCUS

$30.14 +0.62 (+2.10%)

As of 08/21/2026 03:58 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Telix Pharmaceuticals NASDAQ:TLX

$11.33 -1.09 (-8.78%)

As of 08/21/2026 04:00 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANNX, TLX, DNLI, and RCUS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANNX, TLX, DNLI, and RCUS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANNX, TLX, DNLI, and RCUS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX, TLX, DNLI, and RCUS Company Descriptions

Annexon NASDAQ:ANNX

Denali Therapeutics NASDAQ:DNLI

Arcus Biosciences NYSE:RCUS

Telix Pharmaceuticals NASDAQ:TLX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANNX, TLX, DNLI, and RCUS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANNX, TLX, DNLI, and RCUS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANNX, TLX, DNLI, and RCUS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX, TLX, DNLI, and RCUS Company Descriptions

Annexon NASDAQ:ANNX

Denali Therapeutics NASDAQ:DNLI

Arcus Biosciences NYSE:RCUS

Telix Pharmaceuticals NASDAQ:TLX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools